NCT06264531View on ClinicalTrials.gov

Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Cerebral AV Malformation
Interventions
DRUG

Bevacizumab

Bevacizumab 5 mg/kg as a slow infusion over 90 minutes every 14 days for a total of 6 injections

DRUG

Placebo

NaCl 0.9% slow infusion over 90 minutes every 14 days for a total of 6 injections

All Listed Sponsors
lead

Fondation Ophtalmologique Adolphe de Rothschild

NETWORK

NCT06264531 - Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations | Biotech Hunter | Biotech Hunter